To assist with maintenance of ventilator devices being used to combat the coronavirus pandemic, Uscom (ASX: UCM) has released the SpiroSonic VENTITEST ventilator testing device which will allow medical professionals to calibrate ventilators, making it the first digital ultrasonic calibrator of its kind.
With the need for ventilators having risen dramatically as the world grapples COVID-19, ventilator sales have dramatically increased as the final line of defence in intensive care units against the virus.
In order to maintain the effectiveness of respiratory assist devices, regular calibration is required and Uscom’s VENTITEST provides precise measurement of the flow, pressure and volume output of respiratory devices including ventilators, anaesthesia devices and respiratory drug administration devices.
“Uscom devices are developed to set new standards of accuracy and cost-effectiveness, and the VENTITEST is another of our premium products,” said Uscom Chairman, Professor Rob Phillips.
“The VENTITEST will be sold into hospitals, respiratory device manufacturers and home consumers across the world, all of which depend on accurate calibration of their respiratory devices for effective operation and optimal clinical outcomes.”
“The global medical ventilators market is one of the fastest-growing segments in medical devices, and while it’s not difficult to manufacture ventilators, ventilator calibration requires technology with high levels of precision, and our ultrasonic sensors have been in development and clinical use for over 15 years.”
Accompanying the calibration device, VENTITEST-S software records data and reports on devices calibrated, adding an additional recurring revenue stream for Uscom under their Calibration-as-a-Service model.
The Company expects to receive regulatory approval for the sale of VENTITEST into China, SE Asia and the United States within three months with the product qualifying for accelerated approval pathways.
According to Uscom, the global ventilator market was predicted, before COVID-19, to reach ~$2.8B (USD) in 2020 and further reach $27B by 2027. It is estimated the US alone requires an additional 880,000 ventilators to deal with the current COVID-19 pandemic.
Alfred Chan is a Business Reporter at The Sentiment specialising in ASX-listed small cap companies, a bloodstock enthusiast and former equities analyst.
Latest posts by Alfred Chan (see all)
- Harris Technology to expand refurbished tech division amid rising demand from cost-conscious Australians - April 30, 2025
- Harris Technology secures major investment from Taiwan’s FSP Technology at 100% premium - March 10, 2025
- ARC Funds acquires 30% of auzbiz Capital as latest direct-to-investor marketing venture - October 8, 2024
Leave a Comment
You must be logged in to post a comment.